Bone biomarkers in de novo renal transplant recipients

[en] Successful kidney transplantation (partly) corrects the physiologic and metabolic abnormalities driving chronic kidney disease – mineral and bone disorders. At the same time, renal transplant recipients are exposed to immunosuppressive agents that may affect bone metabolism. Bone biomarkers have been suggested as surrogates of or adjuncts to bone biopsy and imaging techniques to assess bone health and to classify risk of bone loss and fractures. Bone biomarkers may be classified as circulating factors that affect bone metabolism (commonly referred to as bone metabolism markers) or that reflect bone cell number and/or activity (commonly referred to as bone turnover markers). A growing body of evidence shows that successful renal transplantation has a major impact on both bone metabolism and bone turnover. Analytical issues, including the cross-reactivity with fragments, complicate the interpretation of bone biomarkers, especially in the setting of a rapid changing kidney function, as is the case after successful renal transplantation. Overall, bone turnover seems to decline following renal transplantation, but inter-individual variability is substantial. Preliminary evidence indicates that bone biomarkers may be useful in guiding mineral and bone therapy in renal transplant recipients.

Disciplines :

Laboratory medicine & medical technology

Author, co-author :

Evenepoel, Pieter

Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

D'Haese, Patrick C.

Language :

English

Title :

Bone biomarkers in de novo renal transplant recipients

Publication date :

February 2020

Journal title :

Clinica Chimica Acta

ISSN :

0009-8981

eISSN :

1873-3492

Publisher :

Elsevier, Netherlands

Volume :

501

Pages :

179 - 185

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.sciencedirect.com/science/article/pii/S0009898119320996

Available on ORBi :

since 13 February 2020

Statistics

Number of views

47 (5 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Moe, S., Drueke, T., Definition, Cunningham J, et al. evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69 (2006), 1945–1953.
Evenepoel, P., Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin. Nephrol. 33 (2013), 191–203.
Alshayeb, H.M., Josephson, M.A., Sprague, S.M., CKD-mineral and bone disorder management in kidney transplant recipients. Am. J. Kidney Dis. 61 (2013), 310–325.
Evenepoel, P., Behets, G.J.S., Laurent, M.R., D'Haese, P.C., Update on the role of bone biopsy in the management of patients with CKD-MBD. J. Nephrol. 30 (2017), 645–652.
Torres, P.U., Bover, J., Mazzaferro, S., de Vernejoul, M.C., Cohen-Solal, M., When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin. Nephrol. 34 (2014), 612–625.
Luckman, M., Hans, D., Cortez, N., et al. Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 12 (2017), 644–652.
Evenepoel, P., Cavalier, E., D'Haese, P.C., Biomarkers predicting bone turnover in the setting of CKD. Curr. Osteoporos. Rep. 15 (2017), 178–186.
Eastell, R., Szulc, P., Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 5 (2017), 908–923.
Seeman, E., Nguyen, T.V., Bone remodeling markers: so easy to measure, so difficult to interpret. Osteoporos. Int. 27 (2016), 33–35.
Amling, M., Herden, S., Posl, M., Hahn, M., Ritzel, H., Delling, G., Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J. Bone Miner. Res. 11 (1996), 36–45.
Naylor, K., Eastell, R., Bone turnover markers: use in osteoporosis. Nat. Rev. Rheumatol. 8 (2012), 379–389.
Cavalier, E., Delanaye, P., Moranne, O., Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am. J. Kidney Dis. 61 (2013), 847–848.
Sardiwal, S., Gardham, C., Coleman, A.E., Stevens, P.E., Delaney, M.P., Lamb, E.J., Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int. 82 (2012), 100–105.
Chavassieux, P., Portero-Muzy, N., Roux, J.P., Garnero, P., Chapurlat, R., Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?. J. Clin. Endocrinol. Metab 100 (2015), 4662–4668.
Souberbielle, J.C., Roth, H., Fouque, D.P., Parathyroid hormone measurement in CKD. Kidney Int 77 (2009), 93–100.
Evenepoel, P., Bover, J., Urena, T.P., Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int. 90 (2016), 1184–1190.
Slatopolsky, E., Finch, J., Clay, P., et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 58 (2000), 753–761.
Delanaye, P., Paquot, F., Bouquegneau, A., et al. Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol. Dial. Transplant., 2017.
De, M.A., Maudsley, S., Azmi, A., et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis. Toxins (Basel), 2019, 11.
Araujo, M.J.C.L., BacelarMarques, I.D., Graciolli, F.G., et al. Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin. Kidney Int., 2019.
Evenepoel, P., Rodriguez, M., Ketteler, M., Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?. Semin. Nephrol. 34 (2014), 151–163.
Bonarek, H., Merville, P., Bonarek, M., et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int. 56 (1999), 642–649.
Wolf, M., Weir, M.R., Kopyt, N., et al. A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 100 (2016), 184–193.
Parfitt, A., Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner. Electrolyte Metab 8 (1982), 92–112.
Evenepoel, P., Claes, K., Kuypers, D., Maes, B., Bammens, B., Vanrenterghem, Y., Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol. Dial. Transplant. 19 (2004), 1281–1287.
Evenepoel, P., Behets, G.J., Viaene, L., D'Haese, P.C., Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int. 91 (2017), 469–476.
Borchhardt, K.A., Sulzbacher, I., Benesch, T., Födinger, M., Sunder-Plassmann, G., Haas, M., Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am. J. Transplant. 7 (2007), 2515–2521.
Evenepoel, P., Claes, K., Meijers, B., et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int., 2019.
Perrin, P., Caillard, S., Javier, R.M., et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am. J. Transplant. 13 (2013), 2653–2663.
Heaf, J., Tvedegaard, E., Kanstrup, I.L., Fogh-Andersen, N., Hyperparathyroidism and long-term bone loss after renal transplantation. Clin. Transplant. 17 (2003), 268–274.
Nishiyama, K.K., Pauchard, Y., Nikkel, L.E., et al. Longitudinal HR-pQCT and image registration detects endocortical bone loss in kidney transplantation patients. J. Bone Miner. Res. 30 (2015), 554–561.
Iyer, S.P., Nikkel, L.E., Nishiyama, K.K., et al. Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton. J. Am. Soc. Nephrol. 25 (2014), 1331–1341.
Evenepoel, P., Cooper, K., Holdaas, H., et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am. J. Transplant. 14 (2014), 2545–2555.
Cruzado, J.M., Moreno, P., Torregrosa, J.V., et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J. Am. Soc. Nephrol. 27 (2016), 2487–2494.
Trillini, M., Cortinovis, M., Ruggenenti, P., et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J. Am. Soc. Nephrol. 26 (2015), 1205–1214.
Baron, R., Kneissel, M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19 (2013), 179–192.
Pelletier, S., Dubourg, L., Carlier, M.C., Hadj-Aissa, A., Fouque, D., The relation between renal function and serum sclerostin in adult patients with CKD. Clin. J. Am. Soc. Nephrol. 8 (2013), 819–823.
Cejka, D., Marculescu, R., Kozakowski, N., et al. Renal elimination of sclerostin increases with declining kidney function. J. Clin. Endocrinol. Metab. 99 (2014), 248–255.
Sabbagh, Y., Graciolli, F.G., O'Brien, S., et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone Miner. Res. 27 (2012), 1757–1772.
Evenepoel, P., Claes, K., Viaene, L., et al. Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation 100 (2016), 2188–2193.
Bonani, M., Rodriguez, D., Fehr, T., et al. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press. Res. 39 (2014), 230–239.
Tomei, P., Zaza, G., Granata, S., et al. Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients. Transplant. Proc. 46 (2014), 2241–2246.
Gifre, L., Ruiz-Gaspa, S., Monegal, A., et al. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57 (2013), 272–276.
Kawazoe, M., Kaneko, K., Shikano, K., Kusunoki, N., Nanki, T., Kawai, S., Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. Clin. Rheumatol. 37 (2018), 2169–2178.
Pereira, R.C., Valta, H., Tumber, N., et al. Altered osteocyte-specific protein expression in bone after childhood solid organ transplantation. PLoS ONE, 10, 2015, e0138156.
Cejka, D., Herberth, J., Branscum, A.J., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 6 (2011), 877–882.
de Oliveira, R.A., Barreto, F.C., Mendes, M., et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 87 (2015), 1039–1045.
Tartaglione, L., Pasquali, M., Rotondi, S., et al. Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS ONE, 12, 2017, e0178637.
Bhan, I., Shah, A., Holmes, J., et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?. Kidney Int. 70 (2006), 1486–1494.
Evenepoel, P., Naesens, M., Claes, K., Kuypers, D., Vanrenterghem, Y., Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am. J. Transplant. 7 (2007), 1193–1200.
Delucchi, A., Toro, L., Alzamora, R., et al. Glucocorticoids decrease longitudinal bone growth in paediatric kidney transplant recipients by stimulating the FGF23/FGFR3 signalling pathway. J. Bone Miner. Res., 2019.
Evenepoel, P., Meijers, B.K., De, J.H., et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin. J. Am. Soc. Nephrol. 3 (2008), 1829–1836.
Wolf, M., Molnar, M.Z., Amaral, A.P., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J. Am. Soc. Nephrol. 22 (2011), 956–966.
Kanaan, N., Claes, K., Devogelaer, J.P., et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin. J. Am. Soc. Nephrol. 5 (2010), 1887–1892.
Sitara, D., Kim, S., Razzaque, M.S., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet., 4, 2008, e1000154.
Stilgren, L.S., Rettmer, E., Eriksen, E.F., Hegedus, L., Beck-Nielsen, H., Abrahamsen, B., Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 35 (2004), 256–265.
Hofbauer, L.C., Khosla, S., Dunstan, C.R., Lacey, D.L., Spelsberg, T.C., Riggs, B.L., Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999), 4367–4370.
Kondo, T., Kitazawa, R., Yamaguchi, A., Kitazawa, S., Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J. Cell. Biochem. 103 (2008), 335–345.
Scialla, J.J., Leonard, M.B., Townsend, R.R., et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6 (2011), 2612–2619.
Nakashima, A., Yorioka, N., Doi, S., Takasugi, N., Shigemoto, K., Kohno, N., Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos. Int. 17 (2006), 841–846.
Sato, T., Tominaga, Y., Iwasaki, Y., et al. Osteoprotegerin levels before and after renal transplantation. Am. J. Kidney Dis. 38 (2001), S175–S177.
Bargnoux, A.S., Dupuy, A.M., Garrigue, V., Deleuze, S., Cristol, J.P., Mourad, G., Renal transplantation decreases osteoprotegerin levels. Transplant. Proc. 38 (2006), 2317–2318.
Hjelmesaeth, J., Ueland, T., Flyvbjerg, A., et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J. Am. Soc. Nephrol. 17 (2006), 1746–1754.
Kodras, K., Haas, M., Effect of kidney transplantation on bone. Eur. J. Clin. Invest. 36 (2006), 63–75.
Reinhardt, W., Bartelworth, H., Jockenhövel, F., et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol. Dial. Transplant. 13 (1998), 436–442.
Schreiber, P.W., Bischoff-Ferrari, H.A., Boggian, K., et al. Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation. PLoS One, 13, 2018 e0191167.
Cavalier, E., Lukas, P., Carlisi, A., Gadisseur, R., Delanaye, P., Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin. Chim. Acta 425 (2013), 117–118.
Bonani, M., Frey, D., Brockmann, J., et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am. J. Transplant. 16 (2016), 1882–1891.
Evenepoel, P., Claes, K., Meijers, B., et al. Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol. Dial. Transplant., 2018.
Yamada, S., Inaba, M., Kurajoh, M., et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin. Endocrinol. (Oxf) 69 (2008), 189–196.
Cavalier, E., Souberbielle, J.C., Gadisseur, R., Dubois, B., Krzesinski, J.M., Delanaye, P., Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin. Biochem. 47 (2014), 1227–1230.
Rojas, E., Carlini, R.G., Clesca, P., et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int. 63 (2003), 1915–1923.
Keronen, S., Martola, L., Finne, P., Burton, I.S., Kroger, H., Honkanen, E., Changes in bone histomorphometry after kidney transplantation. Clin. J. Am. Soc. Nephrol. 14 (2019), 894–903.
Bjarnason, N.H., Henriksen, E.E., Alexandersen, P., Christgau, S., Henriksen, D.B., Christiansen, C., Mechanism of circadian variation in bone resorption. Bone 30 (2002), 307–313.
Swolin-Eide, D., Hansson, S., Magnusson, P., A 3-year longitudinal study of skeletal effects and growth in children after kidney transplantation. Pediatr. Transplant., 2018.
Shidara, K., Inaba, M., Okuno, S., et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif. Tissue Int. 82 (2008), 278–287.
Wu, Y., Lee, J.W., Uy, L., et al. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. J. Pharm. Biomed. Anal. 49 (2009), 1203–1212.
Marques, I.D.B., Araujo, M.J.C.L., Graciolli, F.G., et al. A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J. Am. Soc. Nephrol. 30 (2019), 355–365.
Drueke, T.B., Evenepoel, P., The bone after kidney transplantation. Clin. J. Am. Soc. Nephrol. 14 (2019), 795–797.
Evenepoel, P., Claes, K., Meijers, B., et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 95 (2019), 1461–1470.